Oculis Holding AG(OCS)Earnings, Financials & Key Ratios
OCS•NASDAQ
Price updated Jun 19, 2026
AboutOculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.Show more
- Revenue$0-100.0%
- EBITDA-$79M-8.7%
- Net Income-$95M-10.2%
- EPS (Diluted)-1.81+14.6%
- ROE-70.09%+31.7%
OCS Key Insights
Oculis Holding AG (OCS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 44.7% over 5 years
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Shares diluted 29.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OCS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OCS Price & Volume
Oculis Holding AG (OCS) stock price & volume — 10-year historical chart
Loading chart...
OCS Growth Metrics
Oculis Holding AG (OCS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM7.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM27%
Return on Capital
10 Years-83.59%
5 Years-79.82%
3 Years-92.35%
Last Year-57.44%
OCS Recent Earnings
Oculis Holding AG (OCS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.63-28.6%
$0.49
Rev
$253,185-0.2%
$253,794
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.51-6.7%
$0.48
Rev
$518,435+262.8%
$142,917
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.40+20.0%
$0.50
Rev
$305,460+123.2%
$136,870
Q3 2025
Aug 21, 2025Metric
Actual
Est
EPS
$0.59-11.3%
$0.53
Rev
$328,476+129.2%
$143,340
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.63vs $0.49-28.6% | $253,185vs $253,794-0.2% |
| Q2 2026 | Mar 3, 2026 | $0.51vs $0.48-6.7% | $518,435vs $142,917+262.8% |
| Q4 2025 | Nov 10, 2025 | $0.40vs $0.50+20.0% | $305,460vs $136,870+123.2% |
| Q3 2025 | Aug 21, 2025 | $0.59vs $0.53-11.3% | $328,476vs $143,340+129.2% |
Based on last 12 quarters of dataView full earnings history →
OCS Peer Comparison
Oculis Holding AG (OCS) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 KALA | 79.17M | 3.61 | -1.09 | -13.36% | ||||
 LENZ | 192.83M | 6.15 | -2.16 | -5.19% | -46.82% | 0.00 | ||
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 | |||
 REPL | 841.41M | 10.19 | -3.32 | -102.69% | 0.18 | |||
 AEYE | 78.83M | 6.31 | -25.24 | 14.52% | -9.05% | -70.95% | 2.75 |
Compare OCS vs Peers
Oculis Holding AG (OCS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OCS Income Statement
Oculis Holding AG (OCS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 686K | 0 | 504K |
Revenue Growth % | - | - | - | - | - | -100% | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 52.08M | 0 | 15.07M |
COGS % of Revenue | - | - | - | - | 7592.27% | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -51.4M▲ 0% | 0▲ 100.0% | -14.56M▲ 0% |
Gross Margin % | - | - | - | - | -7492.27% | - | -2889.37% |
Gross Profit Growth % | - | - | - | - | - | 100% | - |
Operating Expenses | 12.34M | 13.23M | 32.38M | 80.71M | 21.81M | 79.15M | 69.81M |
OpEx % of Revenue | - | - | - | - | 3178.86% | - | - |
Selling, General & Admin | 3.52M | 4.1M | 6.74M | 14.72M | 21.81M | 24.63M | 27.55M |
SG&A % of Revenue | - | - | - | - | 3178.86% | - | - |
Research & Development | 9.34M | 9.57M | 22.22M | 29.25M | 52.08M | 54.52M | 56.48M |
R&D % of Revenue | - | - | - | - | 7592.27% | - | - |
Other Operating Expenses | -516K | -433K | 3.41M | 36.74M | -52.08M | 0 | -1000K |
Operating Income | -12.34M▲ 0% | -13.23M▼ 7.3% | -32.38M▼ 144.7% | -80.71M▼ 149.3% | -73.2M▲ 9.3% | -79.15M▼ 8.1% | -84.37M▲ 0% |
Operating Margin % | - | - | - | - | -10671.14% | - | -16740.95% |
Operating Income Growth % | - | -7.26% | -144.68% | -149.3% | 9.3% | -8.12% | - |
EBITDA | -12.11M | -13M | -32.08M | -80.43M | -72.8M | -79.15M | -83.95M |
EBITDA Margin % | - | - | - | - | -10611.95% | - | -16657.14% |
EBITDA Growth % | - | -7.34% | -146.8% | -150.73% | 9.49% | -8.72% | -8.47% |
D&A (Non-Cash Add-back) | 228K | 235K | 299K | 287K | 406K | 0 | 422.43K |
EBIT | -12.34M | -13.4M | -32.2M | -87.38M | -73.2M | -79.15M | -85.17M |
Net Interest Income | -2.62M | -5.1M | -6.32M | 126.86K | 1.53M | 894.88K | 957.61K |
Interest Income | 10K | 21K | 126K | 1.59M | 1.53M | 1.69M | 1.76M |
Interest Expense | 2.63M | 5.12M | 6.44M | 1.46M | 0 | 795.55K | 801.45K |
Other Income/Expense | -2.45M | -5.29M | -6.27M | -7.98M | -12.73M | -15.54M | -10.98M |
Pretax Income | -14.79M▲ 0% | -18.52M▼ 25.2% | -38.64M▼ 108.6% | -88.69M▼ 129.5% | -85.94M▲ 3.1% | -94.69M▼ 10.2% | -95.35M▲ 0% |
Pretax Margin % | - | - | - | - | -12527.26% | - | -18919.18% |
Income Tax | 83K | 27K | 55K | 107K | -160K | 177.64K | -291.8K |
Effective Tax Rate % | -0.56% | -0.15% | -0.14% | -0.12% | 0.19% | -0.19% | 0.31% |
Net Income | -14.87M▲ 0% | -18.55M▼ 24.7% | -38.7M▼ 108.6% | -88.8M▼ 129.5% | -85.78M▲ 3.4% | -94.51M▼ 10.2% | -95.06M▲ 0% |
Net Margin % | - | - | - | - | -12503.94% | - | -18861.29% |
Net Income Growth % | - | -24.74% | -108.59% | -129.47% | 3.41% | -10.18% | 7.62% |
Net Income (Continuing) | -14.87M | -18.55M | -38.7M | -88.8M | -85.78M | -94.86M | -95.06M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.45▲ 0% | -0.57▼ 26.7% | -1.18▼ 107.0% | -2.97▼ 151.7% | -2.12▲ 28.6% | -1.81▲ 14.6% | -1.61▲ 0% |
EPS Growth % | - | -26.67% | -107.02% | -151.69% | 28.62% | 14.62% | 27% |
EPS (Basic) | -0.45 | -0.57 | -1.18 | -2.97 | -2.12 | -1.81 | - |
Diluted Shares Outstanding | 32.73M | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M | 58.91M |
Basic Shares Outstanding | 32.73M | 32.73M | 32.73M | 29.9M | 40.41M | 52.36M | 58.91M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
OCS Balance Sheet
Oculis Holding AG (OCS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 6.16M | 47.98M | 23.66M | 101.02M | 104.9M | 219.14M | 226.36M |
Cash & Short-Term Investments | 4.95M | 46.28M | 19.79M | 91.65M | 98.66M | 213.25M | 221.37M |
Cash Only | 4.95M | 46.28M | 19.79M | 38.33M | 27.71M | 81.42M | 64.37M |
Short-Term Investments | 0 | 0 | 0 | 53.32M | 70.95M | 131.83M | 157M |
Accounts Receivable | 1.14M | 0 | 0 | 7.95M | 777K | 994.13K | 1.57M |
Days Sales Outstanding | - | - | - | - | 413.42 | - | 464.47 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 1K | 911K | 1.08M | 0 | 0 | 4.89M | 0 |
Total Non-Current Assets | 10.22M | 10.06M | 13.4M | 13.34M | 15.46M | 17.09M | 16.91M |
Property, Plant & Equipment | 1.44M | 1.29M | 1.12M | 1.04M | 1.69M | 3M | 2.86M |
Fixed Asset Turnover | - | - | - | - | 0.41x | - | 0.19x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 8.72M | 8.72M | 12.21M | 12.21M | 13.29M | 13.31M | 13.25M |
Long-Term Investments | 50K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 52K | 74K | 89K | 476K | 785.89K | 793.62K |
Total Assets | 16.38M▲ 0% | 58.04M▲ 254.3% | 37.06M▼ 36.2% | 114.35M▲ 208.6% | 120.35M▲ 5.2% | 236.23M▲ 96.3% | 243.26M▲ 0% |
Asset Turnover | - | - | - | - | 0.01x | - | 0.00x |
Asset Growth % | - | 254.29% | -36.15% | 208.56% | 5.25% | 96.28% | 179.96% |
Total Current Liabilities | 4.34M | 4.06M | 12.02M | 19.09M | 44.23M | 36.79M | 43.73M |
Accounts Payable | 790K | 824K | 3.87M | 7.6M | 5.87M | 1.8M | 4.48M |
Days Payables Outstanding | - | - | - | - | 41.14 | - | 52.75 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 502.57K | 414.76K |
Deferred Revenue (Current) | 3.37M | 0 | 0 | 5.95M | 0 | 0 | 0 |
Other Current Liabilities | -1K | 0 | 1 | -497K | 19.85M | 34.48M | 35.44M |
Current Ratio | 1.42x | 11.81x | 1.97x | 5.29x | 2.37x | 5.96x | 5.18x |
Quick Ratio | 1.42x | 11.81x | 1.97x | 5.29x | 2.37x | 5.96x | 5.18x |
Cash Conversion Cycle | - | - | - | - | - | - | 411.72 |
Total Non-Current Liabilities | 55.7M | 114.94M | 123.03M | 1.54M | 2.73M | 3.15M | 3.47M |
Long-Term Debt | 53.98M | 113.5M | 122.45M | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 645K | 577K | 491K | 431K | 865K | 1.81M | 6.4M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.07M | 857K | 91K | 1.11M | 1.87M | 1.34M | 1.65M |
Total Liabilities | 60.04M | 119M | 135.05M | 20.63M | 46.97M | 39.94M | 47.2M |
Total Debt | 54.81M | 114.27M | 123.08M | 605K | 1.18M | 2.32M | 2.24M |
Net Debt | 49.86M | 68M | 103.3M | -37.72M | -26.53M | -79.11M | -62.13M |
Debt / Equity | - | - | - | 0.01x | 0.02x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | 0.74x |
Interest Coverage | -4.69x | -2.62x | -5.00x | -59.71x | - | -99.49x | -106.26x |
Total Equity | -43.65M▲ 0% | -60.95M▼ 39.6% | -97.99M▼ 60.8% | 93.73M▲ 195.6% | 73.38M▼ 21.7% | 196.29M▲ 167.5% | 196.06M▲ 0% |
Equity Growth % | - | -39.63% | -60.76% | 195.65% | -21.71% | 167.49% | 252.02% |
Book Value per Share | -1.33 | -1.86 | -2.99 | 3.13 | 1.82 | 3.75 | 3.33 |
Total Shareholders' Equity | -43.65M | -60.95M | -97.99M | 93.73M | 73.38M | 196.29M | 196.06M |
Common Stock | 297K | 335K | 39K | 366K | 446K | 587.67K | 618.15K |
Retained Earnings | -53.73M | -72.28M | -110.98M | -199.78M | -285.56M | -384.95M | -412.13M |
Treasury Stock | -100K | -100K | -1K | 0 | -10K | -7.01K | -16.95K |
Accumulated OCI | -1.37M | 656K | 2.21M | -1.4M | -2.5M | 28.31M | 30.1M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OCS Cash Flow Statement
Oculis Holding AG (OCS) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -12.03M | -13.82M | -25.07M | -53.84M | -47.5M | -62.22M | -62.18M |
Operating CF Margin % | - | - | - | - | -6924.05% | - | - |
Operating CF Growth % | - | -14.93% | -81.37% | -114.74% | 11.79% | -30.99% | -92.44% |
Net Income | -14.79M | -18.52M | -38.64M | -88.69M | -85.94M | -94.51M | -95.06M |
Depreciation & Amortization | 228K | 235K | 299K | 287K | 406K | 521.45K | 422.43K |
Stock-Based Compensation | 328K | 328K | 804K | 3.61M | 9.78M | 0 | 4.54M |
Deferred Taxes | 47K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.61M | 4.93M | 6.47M | 43.95M | 14.09M | 31.84M | 26M |
Working Capital Changes | -451K | -791K | 6M | -12.99M | 14.16M | -70.67K | 1.95M |
Change in Receivables | 10K | 233K | -152K | 36K | 247K | 1.9M | -272.05K |
Change in Inventory | -10K | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -649K | 30K | 3.04M | 3.73M | -1.71M | -1.86M | 689.65K |
Cash from Investing | -19K | -28K | -3.55M | -54.21M | -17.56M | -59.38M | -35.56M |
Capital Expenditures | -19K | -28K | -65K | -48K | -230K | -1.33M | -292.45K |
CapEx % of Revenue | - | - | - | - | 33.53% | - | 58.03% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -3.48M | 0 | 0 | 0 | -2.09M |
Cash from Financing | 4.86M | 55.19M | 1.71M | 129.67M | 54.03M | 178.6M | 105.86M |
Debt Issued (Net) | -98K | -98K | -159K | -158K | -274K | 0 | -183K |
Equity Issued (Net) | 5.03M | 56.1M | 2.03M | 135.62M | 53.54M | 178.95M | 107.16M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -4K |
Other Financing | -68K | -804K | -157K | -5.79M | 763K | -356.23K | -1.12M |
Net Change in Cash | -7.2M▲ 0% | 41.33M▲ 674.0% | -26.49M▼ 164.1% | 18.54M▲ 170.0% | -10.62M▼ 157.3% | 57.17M▲ 638.4% | 3.82M▲ 0% |
Free Cash Flow | -12.05M▲ 0% | -13.85M▼ 15.0% | -28.62M▼ 106.6% | -53.89M▼ 88.3% | -47.73M▲ 11.4% | -62.51M▼ 31.0% | -62.47M▲ 0% |
FCF Margin % | - | - | - | - | -6957.58% | - | -12395.37% |
FCF Growth % | - | -14.98% | -106.61% | -88.29% | 11.44% | -30.97% | -14.43% |
FCF per Share | -0.37 | -0.42 | -0.87 | -1.80 | -1.18 | -1.19 | -1.06 |
FCF Conversion (FCF/Net Income) | 0.81x | 0.75x | 0.65x | 0.61x | 0.55x | 0.66x | 0.66x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OCS Key Ratios
Oculis Holding AG (OCS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -94.74% | -102.66% | -70.09% | -57.09% |
Return on Invested Capital (ROIC) | -149.85% | -393.39% | -197.47% | -106.75% | -72.37% | -60.61% |
Gross Margin | - | - | - | -7492.27% | - | -2889.37% |
Net Margin | - | - | - | -12503.94% | - | -18861.29% |
Debt / Equity | - | - | 0.01x | 0.02x | 0.01x | 0.01x |
Interest Coverage | -2.62x | -5.00x | -59.71x | - | -99.49x | -106.26x |
FCF Conversion | 0.75x | 0.65x | 0.61x | 0.55x | 0.66x | 0.66x |
Revenue Growth | - | - | - | - | -100% | - |
Related:OCS Dividend History·OCS Revenue History·OCS Price History·OCS P/E History·OCS Financial Ratios·OCS Institutional Holders
OCS Frequently Asked Questions
Oculis Holding AG (OCS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Oculis Holding AG (OCS) reported $0.5M in revenue for fiscal year 2025.
Oculis Holding AG (OCS) saw revenue decline by 100.0% over the past year.
Oculis Holding AG (OCS) reported a net loss of $95.1M for fiscal year 2025.
Dividend & Returns
Oculis Holding AG (OCS) has a return on equity (ROE) of -70.1%. Negative ROE indicates the company is unprofitable.
Oculis Holding AG (OCS) had negative free cash flow of $62.5M in fiscal year 2025, likely due to heavy capital investments.